Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Eli Lilly’s 48% revenue surge eclipses a weak earnings report from The Trade Desk, reshaping market expectations for biotech and ad tech alike.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The company also raised its full‑year revenue forecast, signaling confidence in continued pipeline progress. Coverage of Lilly’s earnings was led by MarketWatch, the Wall Street Journal, Bloomberg, and Quartz, each highlighting the GLP‑1 driven revenue lift and the upgraded guidance. Barron’s offered a deeper analysis with a single‑question focus on the earnings, while MarketWatch also reported the 48% revenue increase.
In contrast, The Trade Desk’s results were reported by MarketWatch, Yahoo Finance, ADWEEK, Benzinga, and the company’s own investor site, emphasizing the earnings miss, the share price plunge, and the modest revenue growth cited by the CEO. The significance of Lilly’s performance lies in the broader market appetite for GLP‑1 therapies, which have become central to treating diabetes and obesity, two conditions with expanding patient populations. The company’s ability to sustain high growth rates has positioned it as a bellwether for biotech firms capitalising on this therapeutic class.
Meanwhile, The Trade Desk operates in a competitive ad‑technology landscape where revenue growth expectations are closely watched; the reported 3% increase and stock decline reflect investor sensitivity to short‑term earnings versus longer‑term strategic positioning. Looking ahead, analysts will monitor Lilly’s upcoming product launches and pipeline milestones that could further validate its guidance, as well as any revisions to its sales outlook in the next earnings cycle. For The Trade Desk, the next quarterly report will be a focal point to assess whether the company can reverse the current share price trajectory and achieve stronger revenue growth, while market participants will watch for any strategic announcements that might address the recent earnings shortfall.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (82% supported) Updated 100d ago.
Quick answers
What drove Eli Lilly’s 48% revenue increase in Q2 2026?
Coverage from MarketWatch and Bloomberg attributes the rise to robust demand for the company’s GLP‑1 diabetes and obesity drugs.
How did The Trade Desk’s stock react to its Q2 earnings?
Yahoo Finance and Benzinga report that the stock fell 21.8% after the company posted sales below analyst estimates.
What guidance did Eli Lilly provide for the full year?
Both the Wall Street Journal and Quartz note that Lilly raised its full‑year revenue forecast following the strong quarterly performance.
Coverage (10)
- Trade Desk shares tumble on earnings miss and weak outlook MarketWatch · 101d ago
- The Trade Desk (NASDAQ:TTD) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 21.8% Yahoo Finance · 101d ago
- The Trade Desk CEO Jeff Green Says Sluggish 3% Revenue Growth ‘Not a Reflection’ of the Company ADWEEK · 101d ago
- The Trade Desk Stock Craters on Q2 Earnings benzinga.com · 101d ago
- The Trade Desk Reports Second Quarter 2026 Financial Results investors.thetradedesk.com · 101d ago
- Eli Lilly Stock: The One Question in Otherwise Perfect Earnings and What It Means for Shares barrons.com · 103d ago
- Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand WSJ · 103d ago
- Lilly’s revenue soars 48%, driven by demand of its GLP-1s MarketWatch · 103d ago
- Lilly Boosts Sales Guidance on Strong Demand for Obesity Drugs Bloomberg.com · 103d ago
- Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast qz.com · 103d ago
Topics
Related trends
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk announces trial data showing Wegovy injection reduces BMI and obesity rates in children as young as six, expanding weight-loss drug use to elementary-age patients.
The GLP-1 boom has a dark side
The FDA orders eye risk warnings on GLP-1 medications like Ozempic and Zepbound, prompting expert guidance.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Millions of Americans are altering their GLP-1 drug regimens, skipping doses and stretching supplies due to cost pressures.
Hundreds of children in England prescribed weight-loss jabs, figures show
Recent figures reveal hundreds of children in England are receiving GLP-1 weight-loss prescriptions.
Makers of obesity drugs hit back at claims of negative side effects
Makers of obesity drugs defend their product safety amid mounting public scrutiny and reports of side effects.